Table 2 Specific targets, assay cohort, and assay performance of liquid biopsy
Indication | Target | Patient type and number | AUC | Sensitivity | Specificity | Reference |
|---|---|---|---|---|---|---|
BC | EV-miRNAs (miR-21, miR-106b, miR-181a, miR-484, and miR-1260b) | BC patients (N = 120), individuals with benign tumors (N = 46), and healthy controls (N = 45) | > 0.8 | 0.5714 | 0.95 | [1] |
BC | EV-miRNAs (miR-607, miR-202-3p, miR-6872-3p, miR-769-3p, miR-5195-3p, miR-4443, miR-4713-3p, miR-6076, and miR-4515) and clinical variables (menopausal status, familiarity, and type of cyst yielded) | GCDB patients (N = 58) and healthy controls (N = 59) | 0.73 (6 EV-miRNAs), 0.8 (3 EV-miRNAs and 3 clinical variables), and 0.8 (2 EV-miRNAs and 2 clinical variables) | / | / | [2] |
TNBC | ECM1, MBL2, and BTD | BC patients and healthy controls (SUM = 30) | / | 0.933 | 0.93 | [3] |
HGSOC | EV protein (CFH, PCP, CCNE1, and CA-125) | HGSOC patients and healthy controls (SUM = 250) | 0.94 (CFH), 0.91 (PCP), 0.83 (CCNE1), and 0.42 (MUC16 (CA-125)) | / | / | [4] |
HGSOC | BST2, MUC1, and sTn | HGSOC patients (N = 58, 17 Stage I, 30 Stage II, and 10 Stage III) and benign ovarian tumor (N = 17) | / | / | / | [5] |
HGSOC | Copy numbers of RAD51, BRCA1, AKT2, CCNE1, and MSH6 | HGSOC patients and cell lines (SUM = 124) | / | / | / | [6] |
CRC | RNF208 | CRC patients (N = 39) and healthy controls (N = 16) | / | / | / | [7] |
CRC | CEA and CD73 | / | 0.975 | / | / | [8] |
COAD | 7 EV proteins | COAD patients (N = 84) and healthy controls (N = 20) | 0.913, 1.000, 0.985, and 0.984 (for Stages I through IV) | / | / | [9] |
PDAC | cf-miRNAs, ex-miRNAs, and CA19-9 | Japan (PAAD patients (N = 150) and healthy controls (N = 102)); the United States (PAAD patients (N = 139) and healthy controls (N = 193)); South Korea (PAAD patients (N = 184) and healthy controls (N = 86)); China (PAAD patients (N = 50) and healthy controls (N = 80)) | 0.97 | 0.95 | 0.96 | [10] |
PDAC | 5-lipids, 2-metabolites, and 5-proteins | early-stage PC patients (N = 60), pancreatitis (N = 39), precursor lesions of pancreas (N = 45), and healthy controls (N = 50) | > 0.95 | > 0.9 | > 0.9 | [11] |
PDAC | ALPPL2 and THBS2 | PDAC patients (N = 26) | / | / | / | [12] |